I give Niagen Bioscience, Inc. a hold rating. The company has a cash-rich balance sheet with no debt and high-quality earnings. Shareholders have already faced 47.5% dilution since 2016, and there ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...

Investing.com - H.C. Wainwright lowered its price target on Lexaria Bioscience (NASDAQ:LEXX) to $4.00 from $5.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $0.90, ...

Coherus Biosciences Inc (NASDAQ:CHRS) just announced that it has kicked off a public offering that will se it unload $125 million worth of its common stock, alongside an additional grant to the ...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

Cogent Biosciences announced highly positive top-line Phase 3 results for bezuclastinib combined with sunitinib in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors (GIST) ...